It is uncertain whether metformin reduces deaths, cardiovascular events, peripheral vascular events, or amputations

Less versus more intravenous fluid did not affect mortality in adults with sepsis

The effectiveness of nirmatrelvir/ritonavir (Paxlovid) in reducing mortality or hospitalization in mild to moderate COVID-19 is uncertain

Adding SGLT-2 inhibitors and GLP-1 agonists to standard treatment reduces death, nonfatal heart attack, and severe kidney disease in Type 2 diabetes, but also increases adverse events

Hypothermia following cardiac arrest does not improve the chance of survival or favorable neurologic outcome

Early angiography in patients with OHCA without ST-elevation does not improve survival or chance of good neurological outcome